AdipoPharma
Latest round
- Series A
Last raised
- Aug 2023
Total raised
- $0.3M
Investors
- 2
About AdipoPharma
Based in France, and founded in 2007, AdipoPharma SAS operates as a life science company that provides treatments for type 2 diabetes. The company was founded by its president, Vincent Marion. As of 2023, the company had 10 employees. AdipoPharma provides and develops drugs for insulin resistance, non-alcoholic fatty liver disease, and type 2 diabetes. The company’s product line includes a therapeutic peptide called PATAS, which is an anti-diabetic drug that reduces comorbidities such as liver steatosis and fibrosis while enhancing cardiovascular and pancreatic functions.
Who invested in AdipoPharma
2 investors across 1 round
See all investors in AdipoPharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Aug 29, 2023
Amount
$0.3M
Investors
Questions about AdipoPharma
Who invested in AdipoPharma?
AdipoPharma has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has AdipoPharma raised?
AdipoPharma has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did AdipoPharma last raise money?
AdipoPharma's most recent round on record is a Series A, in Aug 2023.
What does AdipoPharma do?
Based in France, and founded in 2007, AdipoPharma SAS operates as a life science company that provides treatments for type 2 diabetes.
Where is AdipoPharma headquartered?
AdipoPharma is headquartered in France.
Which VCs invest in companies like AdipoPharma?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at AdipoPharma's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like AdipoPharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.